Share Twitter LinkedIn Facebook Email Michael Wang, M.D. Professor in the department of Lymphoma & Myeloma at MD Anderson Discusses Acalabrutinib Therapy: Infection Rate & Headaches At The 60th ASH Annual Meeting on Dec 1, 2018.
ASH 2025 Lymphoma Highlights: Epcoritamab, S1826, Mosunetuzumab & ctDNA | Dr. Sworder ASH 6 Mins Read
2025 Leukemia / Lymphoma Updates with Aaron Goodman, MD – UC San Diego – MOASC Hematologic Malignancies 6 Mins Read
FDA Approves Adcetris / brentuximab vedotin + lenalidomide & rituximab in relapsed or refractory LBCL: Could This Change Standard Care? Lymphoma 2 Mins Read
